Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer

Parag Parekh, Sanchit Kamble, Nianxi Zhao, Zihua Zeng, Bryce P. Portier, Youli Zu

Research output: Contribution to journalArticlepeer-review

66 Scopus citations


CD30 is highly expressed on Hodgkins lymphoma and anaplastic large cell lymphoma, making it an attractive target for therapy. We describe the generation of serum-stabilized ssDNA aptamers that bind CD30 via a hybrid SELEX methodology. The selected aptamer bound CD30 with high affinity and specificity. Further optimization of the aptamer led to a short, truncated variant with a 50-fold higher affinity than its longer counterpart. The multivalent aptamer was able to induce oligomerization of CD30 receptors and, in effect, activate downstream signaling, which led to apoptosis of ALCL cells. Immunotherapy using aptamer-based co-stimulation provides an alternative to antibodies, and has potential to transform cancer treatment.

Original languageEnglish (US)
Pages (from-to)8909-8917
Number of pages9
Issue number35
StatePublished - Nov 2013


  • ALCL
  • Cancer immunotherapy
  • CD30
  • CHL
  • Lymphoma
  • SsDNA aptamer

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics


Dive into the research topics of 'Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer'. Together they form a unique fingerprint.

Cite this